<<<<<<<<<<<<<<<<<<<<<<<<<<<OVERVIEW>>>>>>>>>>>>>>>>>>
Oral or parenternal for **systemic**
Oral for **mucocutaneous**
Topical for **mucocutaneous**

<<<<<<<<<<<<<<<<<<<<<<<<<<<Amphotericin B>>>>>>>>>>>>>>>>>>
Systemic infection
PK: 
- Insoluble in water, IV. Some lipid-associated delivery. HL 15 days
- 90% plasma protein bound. Mostly metabolized, some renal excretion. 
- Very little reaches CSF. **Intrathecal for fungal meningitis**
MOA:
- Bind ergosterol and form pores in membrane. Some off-target. | Resistance by modifying amount of ergosterol, or modifying the sterol itself.
- Lipid vehicle reduces off-target binding, limit tox.
- Synergistic with Flucytosine
ACTIVITY:
- Yeasts: **Candida albicans** and **Cryptoccus neoformans**
- Endemic mycoses: **Histo, Blasto, Coccidioides**
- Aspergillus
- Mucormycosis
RESITED BY: **Candida lusitaniae and Pseudallescheria boydii**
CLINICAL:
- Used for life-threatening infections. Also at induction to reduce fungal burden, especially in immunocompromised
- Corneal ulcers and Keratitis: Drops | Fungal Arthritis | Candiduria (UTI): No significant systemic tox
AE:
- Infusion: **Dose/Rate** Fever, Chills, Muscle Spasm, Vomiting, Headache, Hypotension. | Anemia, Liver
- Can premedicate with drugs to treat AE.
- Intrathecal: Seizures and arachnoiditis
- **Renal Damage most significatn** - 0.1mg/ml recommended azotemia
  - **Reversible**: Decreased Renal Perfusion
  - **Irreversible**: Renal Tubular Injury
  - **Renal tubular acidosis and potassium/magnesium wasting**

<<<<<<<<<<<<<<<<<<<<<<<<<<Flucytosine>>>>>>>>>>>>>>>>>>>>>>
PK:
- Pyrmidine analog related to 5FU. Narrower spectrum than AmpB. Poor protein binding, penetrate into fluid incl. CSF.
- Glomerular filtration. HL 3-4 hours.
MOA:
- Taken up by cytosine permease. Converts to 5FU > FdUMP > FUTP. Inhibit DNA/RNA synth. 
- **Human cells don't convert to active metabolite.**
- Synergistic with Amp B.
- **Not used alone to prevent resistance. Flu + AmpB: Crypto | Flu + Itra: Chromoblasto**
ACTIVITY: **Crypto, some Candida, Chromoblasto**
AE:
- Renal impairment leads to buildup and tox. Esp. AIDS
- Intestinal flora may convert to active metab.
- Most Commong:: **Cytopenias: Bone marrow tox + anemia, Leukopenia, Thrombocytopenia**
- Derangement of liver enzymes

++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++
<<<<<<<<<<<<<<<<<<<<<<<<<<<<Azoles>>>>>>>>>>>>>>>>>>>>>>>>>
ACTIVITY: Candia, Crypto, Blasto, Coccidio, Histo, Dermatophytes | AmpB-resistant Pseudallescheria boydii
ACTIVITY: **Itraconazole and Voriconazole** active against **Aspergillus**
MOA: **Reduce ergosterol synthesis** by inhibit **P450** | Selective for fungal P450
AE: GI upset, liver abnormalities, 

## Ketoconazole
- Oral
- Less selective than triazoles means **higher incidence of drug interactions + AE**

## Itraconazole
- Oral or IV - Poor CSF
- Reduced BA when taken with rifamycin (Ab used for mycovacterium avium complex)
- CHOICE for Coccidio Histo, Blasto, Sporo. Some Aspergillus, but Voric is DoC now.
- Used for dermatophytoses and onychomycosis
AE: High dose - Hypokalemia, hypertension, edema. | Some rash, hepatitis, hallucination | Heart Failure

## Posaconazole
- Delayed release tablet and oral suspension. **Better absorption with fatty meal**
- **Drug interactions with CYP3A4 substrate: Tacrolimus, Cyclosporine**
- Broadest spectrum of azole.
ACTIVE: Candida and Aspergillus, mucormycosis
CLINICAL: Prophylaxis during chemo and allogeneic bone marrow transplant PT with graft vs Host.

## Fluconazole
- Oral or IV. Water soluble. Good CSF. High BA
- Less common drug interaction because less hepatic enzyme interactions
- Widest therapeutic index of all azoles.
- **Prophylaxis of cyrpto** | **Mucocutaneous candidiasis** (most commonly used)
- Limited dimorphic: Coccidio, histo, blasto
- Reduced fungal disease in bone marrow transplant **recipients** and AIDS
  AE: **Stevens-Johnson Syndrome**, hepatic necrosis, anaphylaxis, alopecia, **congenital anomalies if 1st trimester**

## Voriconazole
- IV and Oral. High BA. Less protein binding than itraconazole. Hepatic metabolism.
- Inhibit human **CYP3A4 - Dose reduction: Cyclosporine, tacrolimus, HMG-CoA reductase inhib**
- Less tox than AmpB

AE: **Visual disturbance (30%) | Phtosensitive dermatitis**
ACTIVITY: **Aspergillus** | Candida, Dimorphic (histo)

<<<<<<<<<<<<<<<<<<<<<<<<Echinicandins>>>>>>>>>>>>>>>>>>>>>
**ACTIVE: Candida and Aspergillus.**
RESISTED: C neoformans and mucormycosis
IV only
MOA: Inhibit synthesis of **B1-3-glucan on fungal cell wall.**
AE: Minor. Some liver elevation.
- Mica incr nifedipine, cyclosporine, sirolimus

## Caspofungin (Cancidas)
- Water soluble, protein bound. HL 9-11 hours, renal excret
- Invasive aspergillosis
## Micafungin (Mycamine)
- Same, but longer HL. 11-15 hour
- Candidemia and prophylaxis

## Anidulafungin (eraxis)
- HL 24 -48 hr
- Esophageal candidiasis 


<<<<<<<<<<<<<<<<<<<<<<<<Terbinafine>>>>>>>>>>>>>>>>>>>>>
- Lipophillic
- Treat dermatophytoses
- Target ergosterol synth.
MOA: Inhib squalene epoxidase -> squalene accumulation and cell death

<<<<<<<<<<<<<<<<<<<<<<<<<<<<<<Topicals>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>
#### Nystatin - Amphoterecin Like.
Only used topically
Little tocivcity
#### Azoles
OFten used for vulvovaginal candidiasis
#### Allylamines
Terbinafine and naftifine
Topicals